Serum apolipoprotein A-I is a novel prognostic indicator for non-metastatic nasopharyngeal carcinoma.
Serum apolipoprotein A-I is a novel prognostic indicator for non-metastatic nasopharyngeal carcinoma.
复制标题
DOI：
10.18632/oncotarget.5823
复制
发表时间：
2015-12-22
期刊：
影响因子：
--
通讯作者：
Cai QQ
中科院分区：
文献类型：
--
作者：
Luo XL;Zhong GZ;Hu LY;Chen J;Liang Y;Chen QY;Liu Q;Rao HL;Chen KL;Cai QQ
目的：探讨术前血清载脂蛋白A-I（ApoA-I）对非转移性鼻咽癌（NPC）TNM分期的补充价值。我们回顾性分析了1196例新诊断的非转移性NPC患者。根据血清ApoA-I水平比较疾病特异性生存率（DSS）、无远处转移生存率（DMFS）和局部无复发生存率（LRFS）。对血清ApoA-I进行多因素分析以评估其预后价值。血清ApoA-I升高或降低的患者的5年DSS、DMFS和LRFS率分别为81.3%和69.3%（P < 0.001）、83.4%和67.4%（P < 0.001）、80.9%和67.3%（P < 0.001）。多因素分析显示ApoA-I ≥ 1.025 g/L是影响上级DSS、DMFS和LRFS的独立预后因素。按临床分期分层后，血清ApoA-I仍是临床和统计学显著的预后预测因子。我们的数据表明，诊断时的ApoA-I水平是一种新的独立的预后指标，可以补充非转移性NPC的风险定义的临床分期。
We investigated the value of pretreatment serum apolipoprotein A-I (ApoA-I) in complementing TNM staging in the prognosis of non-metastatic nasopharyngeal carcinoma (NPC). We retrospectively reviewed 1196 newly diagnosed patients with non-metastatic NPC. Disease-specific survival (DSS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS) rates were compared according to serum ApoA-I level. Multivariate analysis was performed to assess the prognostic value of serum ApoA-I. The 5-year DSS, DMFS, and LRFS rates for patients with elevated or decreased serum ApoA-I were 81.3% versus 69.3% (P < 0.001), 83.4% versus 67.4% (P < 0.001), and 80.9% versus 67.3% (P < 0.001), respectively. ApoA-I ≥ 1.025 g/L was an independent prognostic factor for superior DSS, DMFS, and LRFS in multivariate analysis. After stratification by clinical stage, serum ApoA-I remained a clinically and statistically significant predictor of prognosis. Our data suggest that the level of ApoA-I at diagnosis is a novel independent prognostic marker that could complement clinical staging for risk definition in non-metastatic NPC.